Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024)

Beta Bionics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $321.4 million for Q4 2024.

  • For Q4 2024, Preferred Stock Liabilities rose 22.8% year-over-year to $321.4 million; the TTM value through Dec 2024 reached $321.4 million, up 22.8%, while the annual FY2024 figure was $321.4 million, 22.8% up from the prior year.
  • Preferred Stock Liabilities for Q4 2024 was $321.4 million at Beta Bionics, up from $261.7 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $321.4 million in Q4 2024 and bottomed at $261.7 million in Q4 2023.